All Pathways
Family MedicineDiagnostic

Depression Screening & Initial Management (PHQ-9/USPSTF)

Depression Screening & Initial Management (PHQ-9/USPSTF): Depression Screening → PHQ-2 Initial Screen → PHQ-2 Negative (<3).

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Depression Screening

    USPSTF recommends screening all adults for depression

    1. Action

      PHQ-2 Initial Screen

      2-question screening tool

      • Over last 2 weeks, how often have you:
      • 1. Little interest or pleasure in doing things?
      • 2. Feeling down, depressed, or hopeless?
      • Score 0-3 for each (Not at all=0, Several days=1, More than half=2, Nearly every day=3)
      • Positive screen: Total ≥3
      1. Outcome

        PHQ-2 Negative (<3)

        Rescreen annually or if symptoms develop

      2. Action

        Complete PHQ-9

        Full 9-item depression severity assessment

        • Add 7 more questions covering:
        • Sleep disturbance, fatigue, appetite changes
        • Concentration, psychomotor changes
        • Worthlessness/guilt, suicidal ideation
        • Total score 0-27
        1. Decision

          Question 9 Positive?

          Suicidal ideation assessment

          • Q9: Thoughts of being better off dead or hurting yourself?
          • Any positive response requires immediate safety assessment
          1. Warning

            Immediate Safety Assessment

            Columbia Suicide Severity Rating Scale (C-SSRS)

            • Assess suicidal ideation, intent, plan, means
            • Determine if safe to go home
            • Consider emergency psychiatric evaluation
            • Document safety plan if appropriate
            • Consider hospitalization if high risk
            1. Decision

              PHQ-9 Severity Score

              Determine depression severity

              • 0-4: Minimal depression
              • 5-9: Mild depression
              • 10-14: Moderate depression
              • 15-19: Moderately severe depression
              • 20-27: Severe depression
              1. Action

                Minimal/Mild (0-9)

                Watchful waiting with active support

                • Patient education about depression
                • Lifestyle modifications (exercise, sleep hygiene)
                • Consider brief counseling
                • Reassess PHQ-9 in 2-4 weeks
                • Treatment if persistent >2 weeks or worsening
                1. Action

                  Moderate (10-14)

                  Initiate treatment

                  • Offer choice: antidepressant OR psychotherapy
                  • First-line SSRI: sertraline, escitalopram, fluoxetine
                  • Psychotherapy: CBT or IPT (8-16 sessions)
                  • Patient preference should guide choice
                  • Follow up in 2-4 weeks
                  1. Action

                    SSRI Selection & Dosing

                    First-line antidepressant options

                    • Sertraline: Start 50mg daily, max 200mg
                    • Escitalopram: Start 10mg daily, max 20mg
                    • Fluoxetine: Start 20mg daily, max 80mg
                    • Avoid paroxetine in young adults (discontinuation)
                    • Consider comorbidities in selection
                    1. Action

                      Treatment Follow-Up

                      Monitor response and adjust

                      • Repeat PHQ-9 at each visit
                      • Response: ≥50% reduction in PHQ-9
                      • Remission: PHQ-9 <5
                      • If no response by 4-6 weeks: increase dose or switch
                      • Continue effective treatment 6-12 months minimum
                      1. Outcome

                        Remission Achieved

                        Continue maintenance, monitor for relapse

                      2. Warning

                        Treatment-Resistant

                        Inadequate response to 2+ adequate trials

                        • Refer to psychiatry
                        • Consider augmentation strategies
                        • Rule out bipolar disorder, substance use
                        • Consider TMS or ECT referral for severe cases
              2. Action

                Moderately Severe (15-19)

                Combination therapy recommended

                • Antidepressant + psychotherapy preferred
                • Start SSRI at standard dose
                • Refer for CBT/IPT concurrently
                • Follow up in 1-2 weeks initially
                • Consider psychiatric referral if complex
              3. Warning

                Severe (20-27)

                Urgent psychiatric involvement

                • Combination antidepressant + psychotherapy
                • Consider psychiatric consultation
                • Weekly follow-up initially
                • Assess for hospitalization if functional impairment severe
                • Safety planning mandatory

Guideline Source

USPSTF Screening for Depression and Suicide Risk in Adults

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • PHQ-9 is a screening tool, not diagnostic - clinical interview required
  • Does not replace psychiatric evaluation for complex cases
  • Suicide risk assessment requires immediate safety evaluation
  • Does not address bipolar disorder screening (use MDQ separately)
  • Cultural and language factors may affect scoring validity

Contraindicated Populations

pediatric

Applicable Regions

USAUUKEU

AU: RACGP endorses PHQ-9 for depression screening in primary care

UK: NICE recommends PHQ-9 for case-finding and severity assessment

US: USPSTF Grade B recommendation for adult screening

Version 1Next review: 2028-01-01

Frequently Asked Questions

What is the Depression Screening & Initial Management (PHQ-9/USPSTF)?

The Depression Screening & Initial Management (PHQ-9/USPSTF) is a diagnostic clinical algorithm for Family Medicine. It provides a structured decision tree to guide clinical decision-making, based on USPSTF Screening for Depression and Suicide Risk in Adults.

What guideline is the Depression Screening & Initial Management (PHQ-9/USPSTF) based on?

This algorithm is based on USPSTF Screening for Depression and Suicide Risk in Adults (DOI: 10.1001/jama.2022.21680).

What are the limitations of the Depression Screening & Initial Management (PHQ-9/USPSTF)?

Known limitations include: PHQ-9 is a screening tool, not diagnostic - clinical interview required; Does not replace psychiatric evaluation for complex cases; Suicide risk assessment requires immediate safety evaluation; Does not address bipolar disorder screening (use MDQ separately); Cultural and language factors may affect scoring validity. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Depression Screening & Initial Management (PHQ-9/USPSTF) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free